This is post hoc analysis from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization , Management , and Avoidance ( CHARISMA ) trial of @ patients with prior MI , @ patients with known atherothrombosis , and @ patients with risk factors alone but without heart failure .